vs
Sprinklr, Inc.（CXM）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Sprinklr, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.1倍（$219.1M vs $207.3M），Sprinklr, Inc.净利率更高（1.3% vs -62.0%，领先63.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.2%），Sprinklr, Inc.自由现金流更多（$19.8M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 6.2%）
Sprinklr是美国的一家SaaS企业，专注于客户体验管理（CXM）平台研发。其同名产品整合了社媒营销、社交广告、内容管理、团队协作、员工倡导、客户服务、社媒调研与监测等多类应用模块，为企业提供全链路的客户体验管理解决方案。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CXM vs RARE — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.1M | $207.3M |
| 净利润 | $2.9M | $-128.6M |
| 毛利率 | 66.4% | — |
| 营业利润率 | 5.3% | -54.7% |
| 净利率 | 1.3% | -62.0% |
| 营收同比 | 9.2% | 25.9% |
| 净利润同比 | -72.2% | 3.5% |
| 每股收益（稀释后） | $0.01 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $219.1M | $207.3M | ||
| Q3 25 | $212.0M | $159.9M | ||
| Q2 25 | $205.5M | $166.5M | ||
| Q1 25 | $202.5M | $139.3M | ||
| Q4 24 | $200.7M | $164.6M | ||
| Q3 24 | $197.2M | $139.5M | ||
| Q2 24 | $196.0M | $147.0M | ||
| Q1 24 | $194.2M | $108.8M |
| Q4 25 | $2.9M | $-128.6M | ||
| Q3 25 | $12.6M | $-180.4M | ||
| Q2 25 | $-1.6M | $-115.0M | ||
| Q1 25 | $98.7M | $-151.1M | ||
| Q4 24 | $10.5M | $-133.2M | ||
| Q3 24 | $1.8M | $-133.5M | ||
| Q2 24 | $10.6M | $-131.6M | ||
| Q1 24 | $21.1M | $-170.7M |
| Q4 25 | 66.4% | — | ||
| Q3 25 | 68.2% | — | ||
| Q2 25 | 69.5% | — | ||
| Q1 25 | 71.0% | — | ||
| Q4 24 | 71.2% | — | ||
| Q3 24 | 72.6% | — | ||
| Q2 24 | 73.9% | — | ||
| Q1 24 | 75.5% | — |
| Q4 25 | 5.3% | -54.7% | ||
| Q3 25 | 7.7% | -106.9% | ||
| Q2 25 | -0.9% | -64.8% | ||
| Q1 25 | 5.2% | -102.6% | ||
| Q4 24 | 3.9% | -74.3% | ||
| Q3 24 | -0.0% | -94.6% | ||
| Q2 24 | 2.9% | -79.1% | ||
| Q1 24 | 9.5% | -151.9% |
| Q4 25 | 1.3% | -62.0% | ||
| Q3 25 | 5.9% | -112.8% | ||
| Q2 25 | -0.8% | -69.0% | ||
| Q1 25 | 48.7% | -108.5% | ||
| Q4 24 | 5.2% | -80.9% | ||
| Q3 24 | 0.9% | -95.7% | ||
| Q2 24 | 5.4% | -89.5% | ||
| Q1 24 | 10.9% | -156.8% |
| Q4 25 | $0.01 | $-1.28 | ||
| Q3 25 | $0.05 | $-1.81 | ||
| Q2 25 | $-0.01 | $-1.17 | ||
| Q1 25 | $0.35 | $-1.57 | ||
| Q4 24 | $0.04 | $-1.34 | ||
| Q3 24 | $0.01 | $-1.40 | ||
| Q2 24 | $0.04 | $-1.52 | ||
| Q1 24 | $0.07 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.6M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $558.1M | $-80.0M |
| 总资产 | $1.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $189.6M | $421.0M | ||
| Q3 25 | $125.4M | $202.5M | ||
| Q2 25 | $126.4M | $176.3M | ||
| Q1 25 | $145.3M | $127.1M | ||
| Q4 24 | $93.2M | $174.0M | ||
| Q3 24 | $119.1M | $150.6M | ||
| Q2 24 | $126.8M | $480.7M | ||
| Q1 24 | $164.0M | $112.3M |
| Q4 25 | $558.1M | $-80.0M | ||
| Q3 25 | $543.4M | $9.2M | ||
| Q2 25 | $639.8M | $151.3M | ||
| Q1 25 | $612.1M | $144.2M | ||
| Q4 24 | $497.0M | $255.0M | ||
| Q3 24 | $469.0M | $346.8M | ||
| Q2 24 | $610.9M | $432.4M | ||
| Q1 24 | $679.7M | $140.3M |
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $970.3M | $1.5B | ||
| Q3 24 | $983.8M | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.2B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $19.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | 9.0% | -48.6% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 6.87× | — |
| 过去12个月自由现金流最近4个季度 | $142.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $20.0M | $-99.8M | ||
| Q3 25 | $34.8M | $-91.4M | ||
| Q2 25 | $83.8M | $-108.3M | ||
| Q1 25 | $5.4M | $-166.5M | ||
| Q4 24 | $9.2M | $-79.3M | ||
| Q3 24 | $21.3M | $-67.0M | ||
| Q2 24 | $41.7M | $-77.0M | ||
| Q1 24 | $17.3M | $-190.7M |
| Q4 25 | $19.8M | $-100.8M | ||
| Q3 25 | $34.4M | $-92.7M | ||
| Q2 25 | $83.5M | $-110.7M | ||
| Q1 25 | $4.6M | $-167.8M | ||
| Q4 24 | $8.2M | $-79.5M | ||
| Q3 24 | $19.8M | $-68.6M | ||
| Q2 24 | $39.2M | $-79.0M | ||
| Q1 24 | $15.2M | $-193.9M |
| Q4 25 | 9.0% | -48.6% | ||
| Q3 25 | 16.2% | -58.0% | ||
| Q2 25 | 40.6% | -66.5% | ||
| Q1 25 | 2.3% | -120.5% | ||
| Q4 24 | 4.1% | -48.3% | ||
| Q3 24 | 10.1% | -49.2% | ||
| Q2 24 | 20.0% | -53.7% | ||
| Q1 24 | 7.9% | -178.2% |
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.2% | 0.8% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.4% | 1.0% | ||
| Q4 24 | 0.5% | 0.1% | ||
| Q3 24 | 0.8% | 1.2% | ||
| Q2 24 | 1.3% | 1.4% | ||
| Q1 24 | 1.1% | 3.0% |
| Q4 25 | 6.87× | — | ||
| Q3 25 | 2.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 11.58× | — | ||
| Q2 24 | 3.92× | — | ||
| Q1 24 | 0.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CXM
| License And Service | $190.3M | 87% |
| Professional Services | $28.8M | 13% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
